부산대학교 도서관

The prevalence of type 2 diabetes increases dramatically with age in all populations. This report describes a post‐hoc analysis of eight rosiglitazone monotherapy studies to characterise the efficacy and safety of rosiglitazone in older patients with type 2 diabetes, using a designation of ≥70 years for elderly. A total of 3127 patients were randomised to rosiglitazone (<70 years: n=2099; ≥70 years: n=427) or placebo (<70 years: n=497; ≥70 years: n=104). In both age groups, rosiglitazone 4 mg/day and 8 mg/day reduced HbA1cand fasting plasma glucose compared with baseline and placebo at week 26 with no difference between age groups. There was no difference between the nature, severity or type of adverse events experienced by older or younger patients. Rosiglitazone improves glycaemic control and is well tolerated in older as well as younger patients with type 2 diabetes.